{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:53:44Z","timestamp":1782489224258,"version":"3.54.5"},"reference-count":65,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"unspecified","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,3,31]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate treatment adherence, survival and systemic patient and provider level factors associated with non-Hodgkin\u2019s lymphoma (NHL) management as reported by healthcare providers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Explanatory sequential mixed-methods study comprising a retrospective hospital-based cohort and a qualitative descriptive study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Felege Hiwot Comprehensive Specialized Hospital in Bahir Dar, Ethiopia, and the University of Gondar Comprehensive Specialized Hospital in Gondar, Ethiopia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Adults (\u226518 years) with histologically confirmed NHL who initiated systemic chemotherapy were eligible. We randomly selected 182 patients with NHL treated and diagnosed between 1 August 2019 and 31 July 2024, for retrospective chart review out of a total of 283 patients during the study period. 14 healthcare professionals with at least 1 year of oncology experience participated in in-depth interviews.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome<\/jats:title>\n                    <jats:p>The primary outcome was overall survival, defined as the time from histological diagnosis to death from any cause. The secondary outcome was treatment adherence, defined as interruption between cycles or abandonment of prescribed chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At a median follow-up of 18 months, the estimated 3-year overall survival rate was 48.5% (95% CI 37.8% to 58.4%). Lower survival rate was independently associated with B-symptoms (adjusted HR (AHR) 2.7, 95%\u2009CI 1.6 to 4.4), high intermediate International Prognostic Index (IPI) (AHR 3.7, 95%\u2009CI 1.8 to 6.9) and high IPI (AHR 5.5, 95%\u2009CI 2.7 to 11.3). Treatment abandonment and interruption occurred in 22.5% and 20.5% of patients, respectively. Exposure to rituximab was more likely to abandon therapy (\u03c7\u00b2=4.8, p=0.03). Patient residence in rural areas was associated with higher rates oftreatment interruption (\u03c7\u00b2 = 6.0, p = 0.01), whereas absence of healthinsurance was associated with treatment abandonment (\u03c7\u00b2 = 8.0, p =0.005).<\/jats:p>\n                    <jats:p>In the qualitative analysis, healthcare providers identified multilevel barriers to NHL care, including low patient awareness and late presentation, frequent misdiagnosis at the primary care level, weak referral systems, financial constraints, inconsistent drug availability and limited diagnostic capacity. These systemic and patient-level challenges are often associated with delayed diagnosis, treatment interruption and suboptimal survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>3-year survival among adults with NHL in Northwest Ethiopia was substantially lower than reported in high-income settings. Mortality was higher among patients with B-symptoms and elevated IPI scores. High rates of treatment interruption and abandonment were observed. Patient-level and system-level factors are associated with reduced survival and treatment continuity. Strengthening early diagnosis, risk stratification and financial protection may support improved treatment adherence and survival outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-113991","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:35:49Z","timestamp":1778502949000},"page":"e113991","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment adherence, survival outcomes and barriers to care of non-Hodgkin lymphoma in Northwest Ethiopia: a mixed-methods study"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3431-8187","authenticated-orcid":false,"given":"Abel Temeche","family":"Kassaw","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephrem Tafesse","family":"Teferi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tigabu Eskeziya","family":"Zerihun","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9361-1033","authenticated-orcid":false,"given":"Desalegn Addis","family":"Mussie","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tefri Bihonegn","family":"Melese","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meklit Tadele","family":"Admasu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belayneh Yitayew","family":"Wallie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Medicine and Health Sciences, Wachemo University, Hosaena, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mekuanent Kassa","family":"Birarra","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2026062608315390000_16.5.e113991.1","first-page":"34","article-title":"Lymphoma: Diagnosis and Treatment","volume":"101","author":"Lewis","year":"2020","journal-title":"Am Fam Physician"},{"key":"2026062608315390000_16.5.e113991.2","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7056","article-title":"Global burden, risk factors, and trends of non-Hodgkin lymphoma: A worldwide analysis of cancer registries","volume":"13","author":"Huang","year":"2024","journal-title":"Cancer Med"},{"key":"2026062608315390000_16.5.e113991.3","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1182\/blood-2022-168779","article-title":"Global Burden, Risk Factors, and Trends of Non-Hodgkin Lymphoma in 2020 and Projections to 2040: A Population-Based Study","volume":"140","author":"Chu","year":"2022","journal-title":"Blood"},{"key":"2026062608315390000_16.5.e113991.4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0057"},{"key":"2026062608315390000_16.5.e113991.5","first-page":"199","article-title":"Lymphoma in Sub-Saharan Africa: a scoping review of the epidemiology, treatment challenges, and patient pathways","volume":"36","author":"Baissa","year":"2025","journal-title":"Cancer Causes Control"},{"key":"2026062608315390000_16.5.e113991.6","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71254","article-title":"Epidemiological Profile of Non-Hodgkin\u2019s Lymphomas Seen at Kinshasa University Clinics From 2012 to 2022","volume":"14","author":"Julia","year":"2025","journal-title":"Cancer Med"},{"key":"2026062608315390000_16.5.e113991.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102370","article-title":"Estimates of the global burden of non-Hodgkin lymphoma attributable to HIV: a population attributable modeling study","volume":"67","author":"Chen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026062608315390000_16.5.e113991.8","first-page":"1474","article-title":"Global patterns of non-hodgkin lymphoma in 2020","volume":"151","author":"Mafra","year":"2022","journal-title":"Nt J Cancer"},{"key":"2026062608315390000_16.5.e113991.9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.5074.5074","article-title":"Epidemiology Projection Trends for Non-Hodgkin Lymphoma (NHL) and Its Subtypes in the United States (US) and Europe (EU)","volume":"120","author":"Trask","year":"2012","journal-title":"Blood"},{"key":"2026062608315390000_16.5.e113991.10","doi-asserted-by":"crossref","first-page":"738693","DOI":"10.3389\/fmed.2021.738693","article-title":"Trends Analysis of Non-Hodgkin Lymphoma at the National, Regional, and Global Level, 1990\u20132019: Results From the Global Burden of Disease Study 2019","volume":"8","author":"Cai","year":"2019","journal-title":"Front Med"},{"key":"2026062608315390000_16.5.e113991.11","doi-asserted-by":"crossref","DOI":"10.1177\/10732748261434396","article-title":"Five-Year Survival and Determinants of Diffuse Large B-cell Lymphoma in Resource-Limited Settings: The Impact of HIV\/AIDS in a Multi-Center Cohort Study","volume":"33","author":"Kassaw","year":"2026","journal-title":"Cancer Control"},{"key":"2026062608315390000_16.5.e113991.12","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad157"},{"key":"2026062608315390000_16.5.e113991.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243561","article-title":"Determinants of non-Hodgkin\u2019s lymphoma at Felegehiwot specialized hospital, North West Ethiopia: A case-control study","volume":"15","author":"Chekol","year":"2021","journal-title":"PLoS ONE"},{"key":"2026062608315390000_16.5.e113991.14","unstructured":"health Fmo . National cancer control plan 2016-2020. In: directorate Dpac, (ed.). Ethiopia. 2015."},{"key":"2026062608315390000_16.5.e113991.15","doi-asserted-by":"crossref","unstructured":"Bekalu YE , Wudu MA , Gashu AW . Adherence to chemotherapy and associated factors among patients with cancer in amhara region. Northeastern Ethiopia 2022;30. doi:10.1177\/10732748231185010","DOI":"10.1177\/10732748231185010"},{"key":"2026062608315390000_16.5.e113991.16","doi-asserted-by":"crossref","unstructured":"Abate Y , Solomon K , Azmera YM , et al . Barrier analysis for continuity of palliative care from health facility to household among adult cancer patients in Addis Ababa, Ethiopia. BMC Palliat Care 2023;22:57. doi:10.1186\/s12904-023-01181-w","DOI":"10.1186\/s12904-023-01181-w"},{"key":"2026062608315390000_16.5.e113991.17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15430\/JCP.2019.24.1.33","article-title":"The Situation of Cancer Treatment in Ethiopia: Challenges and Opportunities","volume":"24","author":"Haileselassie","year":"2019","journal-title":"J Cancer Prev"},{"key":"2026062608315390000_16.5.e113991.18","doi-asserted-by":"crossref","first-page":"e889","DOI":"10.1093\/oncolo\/oyac127","article-title":"Burden of Cancer and Utilization of Local Surgical Treatment Services in Rural Hospitals of Ethiopia: A Retrospective Assessment from 2014 to 2019","volume":"27","author":"Wondimagegnehu","year":"2022","journal-title":"Oncologist"},{"key":"2026062608315390000_16.5.e113991.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-041863"},{"key":"2026062608315390000_16.5.e113991.20","unstructured":"Rusthoven JJ . Current approaches to the treatment of advanced-stage non-Hodgkin\u2019s lymphoma. CMAJ: Canadian Medical Association Journal 1987;136."},{"issue":"1149","key":"2026062608315390000_16.5.e113991.21","article-title":"Sample Size Determination in Health Studies: A Practical Manual","volume":"86","author":"Lachenbruch","year":"1991","journal-title":"J Am Stat Assoc"},{"key":"2026062608315390000_16.5.e113991.22","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwk052"},{"key":"2026062608315390000_16.5.e113991.23","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(95)00048-8"},{"key":"2026062608315390000_16.5.e113991.24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1108\/QMR-06-2016-0053","article-title":"Sample size for qualitative research","volume":"19","author":"Boddy","year":"2016","journal-title":"QMR"},{"key":"2026062608315390000_16.5.e113991.25","doi-asserted-by":"crossref","DOI":"10.1186\/s13027-018-0200-y","article-title":"Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience","volume":"13","author":"Cuellar","year":"2018","journal-title":"Infect Agents Cancer"},{"key":"2026062608315390000_16.5.e113991.26","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2147\/CMAR.S361485","article-title":"Treatment Outcomes and Its Associated Factors Among Adult Patients with Selected Solid Malignancies at Kenyatta National Hospital: A Hospital-Based Prospective Cohort Study","volume":"14","author":"Degu","year":"2022","journal-title":"Cancer Manag Res"},{"key":"2026062608315390000_16.5.e113991.27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20999"},{"key":"2026062608315390000_16.5.e113991.28","first-page":"453","article-title":"Extranodal non-Hodgkin\u2019s lymphomas--a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin\u2019s lymphomas","volume":"9","author":"Lal","year":"2008","journal-title":"Asian Pac J Cancer Prev"},{"key":"2026062608315390000_16.5.e113991.29","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600733531"},{"key":"2026062608315390000_16.5.e113991.30","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602540"},{"key":"2026062608315390000_16.5.e113991.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272282","article-title":"Prognostic variables and 4-year survival outcomes in CD20 Positive AIDS-Related Lymphoma in the Anti-retroviral treatment era: A Retrospective Review from a Single Centre in KwaZulu-Natal, South Africa","volume":"17","author":"Rapiti","year":"2022","journal-title":"PLoS ONE"},{"key":"2026062608315390000_16.5.e113991.32","article-title":"Clinical and Therapeutic Profile of Non-Hodgkin\u2019s Lymphoma: A Retrospective Study From a Najran Oncology Center","volume":"15","author":"Badheeb","year":"2023","journal-title":"Cureus"},{"key":"2026062608315390000_16.5.e113991.33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.oooo.2024.09.007","article-title":"Prognostic and survival factors in head and neck extra-nodal non-Hodgkin\u2019s lymphoma","volume":"139","author":"Bello-Castro","year":"2025","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"2026062608315390000_16.5.e113991.34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.14740\/wjon1504","article-title":"Epidemiology and Determinants of Survival for Primary Intestinal Non-Hodgkin Lymphoma: A Population-Based Study","volume":"13","author":"Singh","year":"2022","journal-title":"World J Oncol"},{"key":"2026062608315390000_16.5.e113991.35","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.734616"},{"key":"2026062608315390000_16.5.e113991.36","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/02841860903032825","article-title":"Incidence and survival of gastric non-Hodgkin\u2019s lymphoma: a population-based study from the Association of the French Cancer Registries (FRANCIM)","volume":"48","author":"Danzon","year":"2009","journal-title":"Acta Oncol"},{"key":"2026062608315390000_16.5.e113991.37","doi-asserted-by":"crossref","unstructured":"Yu XQ , Chen WH , O\u2019Connell DL . Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia. BMC Cancer 2010;10:231. doi:10.1186\/1471-2407-10-231","DOI":"10.1186\/1471-2407-10-231"},{"key":"2026062608315390000_16.5.e113991.38","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3324\/haematol.2023.283097","article-title":"The International Prognostic Index: still relevant 30 years later","volume":"108","author":"LaCasce","year":"2023","journal-title":"Haematologica"},{"key":"2026062608315390000_16.5.e113991.39","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00000421-200210000-00016","article-title":"Aggressive non-Hodgkin\u2019s lymphoma treated at the Institute of Oncology, Istanbul: treatment, outcome, and prognostic factors","volume":"25","author":"Alici","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"2026062608315390000_16.5.e113991.40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1634\/theoncologist.3-3-189","article-title":"Prognostic Factors in Aggressive Non-Hodgkin\u2019s Lymphomas","volume":"3","author":"Nicolaides","year":"1998","journal-title":"Oncologist"},{"key":"2026062608315390000_16.5.e113991.41","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3892\/mco.2013.146","article-title":"Significance of clinical factors as prognostic indicators for patients with peripheral T-cell non-Hodgkin lymphoma: A retrospective analysis of 252 cases","volume":"1","author":"Xie","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"2026062608315390000_16.5.e113991.42","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31820c011a"},{"key":"2026062608315390000_16.5.e113991.43","doi-asserted-by":"crossref","unstructured":"Buyego P , Nakiyingi L , Ddungu H , et al . Possible misdiagnosis of HIV associated lymphoma as tuberculosis among patients attending Uganda Cancer Institute. AIDS Res Ther 2017;14:13. doi:10.1186\/s12981-017-0139-x","DOI":"10.1186\/s12981-017-0139-x"},{"key":"2026062608315390000_16.5.e113991.44","article-title":"Treatment outcome and abandonment rates in a retrospective cohort of children with Burkitt lymphoma in Kano, Nigeria","volume":"45","author":"Abdullahi","year":"2019","journal-title":"Nig J Paed"},{"key":"2026062608315390000_16.5.e113991.45","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31997","article-title":"Significant Impact of Treatment Abandonment on Survival of Children With \u201cCommon and Curable\u201d GICC Index Cancers in Sub\u2010Saharan Africa\u2014A Multicenter Prospective CANCaRe Africa Study","volume":"72","author":"Yimer","year":"2025","journal-title":"Pediatr Blood Cancer"},{"key":"2026062608315390000_16.5.e113991.46","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s12325-025-03143-5","article-title":"Analysis of Real-World Progression and Insufficient Response Variables and Related Endpoints Among Patients with Non-Hodgkin Lymphoma","volume":"42","author":"Richey","year":"2025","journal-title":"Adv Ther"},{"key":"2026062608315390000_16.5.e113991.47","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/onco.13915","article-title":"Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma","volume":"26","author":"Johnson","year":"2021","journal-title":"Oncologist"},{"key":"2026062608315390000_16.5.e113991.48","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15785"},{"key":"2026062608315390000_16.5.e113991.49","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-024-01372-5","article-title":"Impact of critical illness on continuation of anticancer treatment and prognosis of patients with aggressive hematological malignancies","volume":"14","author":"Bredin","year":"2024","journal-title":"Ann Intensive Care"},{"key":"2026062608315390000_16.5.e113991.50","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00277-023-05179-5","article-title":"Clinical outcomes after incomplete cycles of R-CHOP for diffuse large B-cell lymphoma: 10 years\u2019 real-world experience in a single institute","volume":"102","author":"Yoon","year":"2023","journal-title":"Ann Hematol"},{"key":"2026062608315390000_16.5.e113991.51","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ajh.25789","article-title":"Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma","volume":"95","author":"W\u00e4sterlid","year":"2020","journal-title":"Am J Hematol"},{"key":"2026062608315390000_16.5.e113991.52","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/ph7050530","article-title":"Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin\u2019s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey","volume":"7","author":"Baer Ii","year":"2014","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026062608315390000_16.5.e113991.53","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-022-08188-8","article-title":"The magnitude and perceived reasons for childhood cancer treatment abandonment in Ethiopia: from health care providers\u2019 perspective","volume":"22","author":"Mirutse","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"2026062608315390000_16.5.e113991.54","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-12294-7","article-title":"Understanding referral of patients with cancer in rural Ethiopia: a qualitative study","volume":"24","author":"Trabitzsch","year":"2024","journal-title":"BMC Cancer"},{"key":"2026062608315390000_16.5.e113991.55","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1093\/oncolo\/oyad032","article-title":"Pathways and Referral of Patients with Cancer in Rural Ethiopia: A Multi-center Retrospective Cohort Study","volume":"28","author":"Trabitzsch","year":"2023","journal-title":"Oncologist"},{"key":"2026062608315390000_16.5.e113991.56","unstructured":"Federal Ministry of Health E . National diagnostics strategic plan. Addis Ababa, 2025."},{"key":"2026062608315390000_16.5.e113991.57","unstructured":"Federal Ministry of Health E . National Cancer Control Plan of Ethiopia 2025-2029. 2025."},{"key":"2026062608315390000_16.5.e113991.58","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/08880018.2022.2139028","article-title":"Chemotherapy supply chain management, safe-handling and disposal in Ethiopia: the case of Tikur Anbessa specialized hospital","volume":"40","author":"Fentie","year":"2023","journal-title":"Pediatr Hematol Oncol"},{"key":"2026062608315390000_16.5.e113991.59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294230","article-title":"Palliative care service utilization and associated factors among cancer patients at oncology units of public hospitals in Addis Ababa, Ethiopia","volume":"19","author":"Afessa","year":"2024","journal-title":"PLoS ONE"},{"key":"2026062608315390000_16.5.e113991.60","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1016\/S2214-109X(25)00138-X","article-title":"Substandard anticancer medications in clinical care settings and private pharmacies in sub-saharan Africa: a systematic pharmaceutical investigation","volume":"13","author":"Wilfinger","year":"2025","journal-title":"Lancet Glob Health"},{"key":"2026062608315390000_16.5.e113991.61","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-024-10864-w","article-title":"The role of a community conversation intervention in reducing stigma related to lower limb lymphoedema in northern Ethiopia","volume":"24","author":"Tora","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"2026062608315390000_16.5.e113991.62","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1016\/S1470-2045(24)00514-X","article-title":"Cancer care and outreach in the South Asian Association for Regional Cooperation (SAARC) region: overcoming barriers and addressing challenges","volume":"25","author":"Huq","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026062608315390000_16.5.e113991.63","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bjh.16617","article-title":"Improving outcomes for non-Hodgkin lymphoma in Sub-Saharan Africa: where to start?","volume":"190","author":"Painschab","year":"2020","journal-title":"Br J Haematol"},{"key":"2026062608315390000_16.5.e113991.64","doi-asserted-by":"crossref","DOI":"10.1200\/GO.23.00104","article-title":"Attitude, Perceived Barriers, and Challenges Toward Implementing Resource-Appropriate Guidelines for Hematologic Malignancies: Physicians\u2019 Survey in Ethiopia","volume":"9","author":"Baissa","year":"2023","journal-title":"JCO Global Oncology"},{"key":"2026062608315390000_16.5.e113991.65","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28760","article-title":"Training pediatric hematologist\/oncologists for capacity building in Ethiopia","volume":"67","author":"Hailu","year":"2020","journal-title":"Pediatr Blood Cancer"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-113991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:42:39Z","timestamp":1782488559000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-113991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":65,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,11]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjopen-2025-113991"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-113991","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}